Answers are grounded in this paper and cite their sources.
Gleevec, the drug hailed for its ability to send people with chronic myeloid leukemia (CML) into remission, is far from perfect. In some patients, white blood cells become resistant to it, allowing cancer to return. Moreover, a significant fraction of newly diagnosed patients start out resistant. But now Bristol-Myers Squibb has developed a new compound, dubbed BMS-354825, that appears to complement the effects of Gleevec (also known as imatinib), and preliminary results suggest that its antileukemia effects may be even more potent, researchers say.
No takes yet. Share an insight, caveat, or question.
John Travis (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: